Mirati sees more responses for KRAS drug in Keytruda combo as it angles for an edge over Amgen
With a filing for its KRAS inhibitor adagrasib right around the corner, Mirati is building a growing case against Amgen as investors watch with bated breath. Promising data from a tiny subgroup of lung cancer patients treated with an adagrasib combo could whet investors’ appetites just enough, but how will Amgen respond?
In a short update in its Q3 earns, Mirati said a combination of adagrasib and Merck’s Keytruda posted four partial responses among eight previously untreated, advanced non-small cell lung cancer patients in a Phase Ib test, casting new hope the biotech could seize a leg up on Amgen in the fledging KRAS inhibitor race.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 157,500+ biopharma pros reading Endpoints daily — and it's free.